Combo Method Reveals Cells' Signal Systems
5/26/2011
Our understanding of what differentiates cancer cells from normal cells is limited by a lack of methods for studying the complex signal systems of individual cells. By combing two different methods, a team of Uppsala researchers have now provided the research world with a tool for studying signal paths on several levels at the same time. Their article is being published today in PLoS One...
The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) (formerly The ASCO Cancer Foundation) is helping people affected by cancer by hosting Answers to Cancer, a public forum dedicated to sharing the latest information on cancer advances and survivorship issues...
VIVUS Announces Positive Phase 3 Results Of Avanafil In Radical Prostatectomy Patients
5/26/2011
VIVUS, Inc. (NASDAQ: VVUS) announced positive results from a phase 3, placebo-controlled clinical trial of the investigational drug avanafil for the treatment of erectile dysfunction (ED) in patients following a radical prostatectomy...
Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
5/26/2011
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months...
Chlorine And Childhood Cancer
5/26/2011
A significant positive association between the risk of childhood leukaemia and levels of chlorine-containing chemicals in the atmosphere has been found by researchers in Portugal. Details are reported in the current issue of the International Journal of Environment and Health...
Improved Prognosis For Esophageal Cancer
5/26/2011
In recent years, the number of cases of adenocarcinoma of the esophagus (or gullet) has been on the rise. At the same time, however, new ways of treatment are improving the outlook for patients. In the current issue of Deutsches Arzteblatt International (Dtsch Artzebl Int 2011; 108[18]: 313 - 9), Angelika Behrens and her working group report on innovations in diagnosis and treatment...
Pieris AG announced preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood. PRS-080 showcases Anticalins' ability to encapsulate small targets like hepcidin with high specificity and potency...
New Type Of Hormone Therapy Extends Prostate Cancer Patients' Lives, Study Finds
5/25/2011
The drug abiraterone acetate gave men with advanced prostate cancer an average of four months of extra life, according to Phase III trial results published in the New England Journal of Medicine today. Abiraterone acetate, trade name Zytiga™, was discovered at The Institute of Cancer Research (ICR) in what is now the Cancer Research UK Cancer Therapeutics Unit...
Regular Acetaminophen Reduces Prostate Cancer Risk
5/25/2011
A man who takes one acetaminophen tablet each day for at least five years has a 38% lower chance of developing prostate cancer compared to other men, researchers from the American Cancer Society reported in Cancer Epidemiology, Biomarkers and Prevention. The authors add that theirs is one of two studies that looked into the consequences of regular acetaminophen use over the long term...
Prostate Cancer Outcomes Improve With Regular Brisk Walking
5/25/2011
If you have been diagnosed with prostate cancer, regular brisk walking can help delay or even stop progression of the disease, scientists from the University of California reported in the journal Cancer Research. They added that regular brisk walking has been found in various studies to have several health benefits. Erin Richman, Sc.D...